GLP1R and kidney disorder: Pending further clinical studies, the use of a sodium-glucose transport protein 2 inhibitor and/or glucagon-like peptide 1 receptor agonist may provide an effective therapy for patients with PKD whose kidney disease discordance is strongly linked to cardiovascular-kidney-metabolic syndrome.